🕐08.10.09 - 11:55 Uhr
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of
Severe (Stage 3) Chronic Pain
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
Nyloxin Rx, which Was Developed by Nutra Pharma’s Drug Discovery Subsidiary, ReceptoPharm, Is a Prescription Medicine Launching in Late-2009 for the Treatment of Severe (Stage 3) Chronic Pain.
PLANTATION, Fla.--Nutra Pharma Corp.
(OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.
Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm.
Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function.
Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.
“For the past 10 years, we have allocated significant time and resources to the study of peptides from cobra venom for the treatment of several indications, including pain,” explained Dr.
Paul Reid, CEO of ReceptoPharm.
“Given the amount of clinical evidence using cobra venom as a pain reliever, the drug’s well-defined safety profile, and the active pharmaceutical ingredient, which is a monographed drug under United States Homeopathic Pharmacopoeia, we plan to go directly to market with Nyloxin Rx and begin introducing it to physicians later this year,” he added.
According to a report published by IMS Health, there were a total of 237 million U.S.
opioid prescriptions in 2008 with over 85 million prescriptions specifically for the treatment of chronic pain.
Additionally, a December 2008 article in the Journal Gazette reported that sales of Oxycodone (not including Percodan) totaled $2.89 billion and that sales of Fentanyl totaled $1.55 billion from January to October of the same year.
“We are excited to be launching Nyloxin Rx as a prescription pain reliever at a time when both physicians and patients are actively looking for alternatives to opioid-based pain therapies.
We are confident that Nyloxin Rx will compete successfully with other prescription pain medicines and become the preferred treatment for severe chronic pain,” commented Rik J.
Deitsch, Chairman and CEO of Nutra Pharma Corporation.
“While we continue to focus on bringing Nyloxin Rx to market, we are also planning to use our financial and strategic resources to begin additional human clinical trials in the near-term for our other drug indications outside of pain,” he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corp.
is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.
Nutra Pharma Corp.
through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.
The Companys subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS").
The Companys subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI).
Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnolog
y arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Nyloxin.com
SEC Disclaimer
This press release contains forward-looking statements.
The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharmas ("the Company") business plan.
The Companys business is subject to various risks, which are discussed in the Companys filings with the Securities and Exchange Commission ("SEC").
Introducing Nyloxin Rx for the treatment of severe (Stage 3) chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock.
The Companys filings may be accessed at the SECs Edgar system at www.sec.gov.
Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.
The Company cautions readers not to place reliance
on such statements.
Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contacts
Nutra Pharma Corp.
David Isserman, 877-895-5647
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=US67060U1097
Mitteilung übermittelt durch IRW-Press.com.
Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.